Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
February 29 2024 - 6:14AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2024
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
29
February 2024 - “Haleon Preliminary 2023 Full Year
Results”
|
|
|
|
99.1
Haleon plc: Preliminary 2023 Full Year Results
29 February 2024: Haleon
plc's preliminary full year results for the year ended 31 December
2023 are available at: http://www.rns-pdf.londonstockexchange.com/rns/8643E_1-2024-2-28.pdf.
The full year results statement will also be available on the
Haleon website www.haleon.com/investors,
and the results have been submitted in full unedited text to the
Financial Conduct Authority's National Storage Mechanism and will
shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Investor Presentation
A recorded results presentation by Brian McNamara, Chief Executive
Officer, and Tobias Hestler, Chief Financial Officer, will be
available shortly after 7am GMT (8am CET) on 29 February 2024 and
can be accessed at www.haleon.com/investors. This
will be followed by a Q&A session at 9am GMT (10am
CET).
For analysts and shareholders wishing to ask questions, please use
the dial-in details below which will have a Q&A
facility:
|
UK:
|
+44 800 279 3956
|
|
US:
|
+1 866 291 4166
|
|
All other:
|
+44 (0) 20 7107 0613
|
|
Passcode:
|
43700369
|
An archived webcast of the presentation will be available later on
the day of the results and can be accessed at www.haleon.com/investors.
This information contains regulated information as per 6.3.7R of
the Disclosure and Transparency Rules of the Financial Conduct
Authority.
|
Enquiries
|
|
Investors
|
Media
|
|
Sonya Ghobrial
|
+44 7392 784784
|
Zoë Bird
|
+44 7736 746167
|
|
Rakesh Patel
|
+44 7552 484646
|
Nidaa Lone
|
+44 7841 400607
|
|
Emma White
|
+44 7823 523562
|
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health,
with a purpose to deliver better everyday health with humanity.
Haleon's product portfolio spans five major categories - Oral
Health, Pain Relief, Respiratory Health, Digestive Health and
Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren,
Theraflu, Otrivin, Polident, parodontax and Centrum - are built on
trusted science, innovation and deep human
understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
Date:
February 29, 2024
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
Haleon (NYSE:HLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Haleon (NYSE:HLN)
Historical Stock Chart
From Apr 2023 to Apr 2024
